The Bull Rankings scorecard — our quality-growth score is 84 / 100, built from three pillars each graded 0–100 against sector peers: Quality 88, Growth 85, Value 79. At today's price, our reverse-DCF read says the market is implicitly betting on about 7% a year in free-cash-flow growth sustained for a decade — a gauge of how much optimism is already in the stock.
The thesis
DOCS trades at $25.75 with a P/E of 30.7, a PEG of 0.59, and $306 million in trailing free cash flow. Our Bull Rankings model hands it an 84‑point Quality‑Growth score, with the Quality pillar at 88 and the Growth pillar at 85—both well above peers—while the Value pillar trails at 79. That split says the business is rock‑solid but the market is demanding a premium for future expansion. The reverse‑DCF implies 7% annual free‑cash‑flow growth for ten years, a rate that outpaces the 11.2% FY revenue growth reported in the quarter ended 2026‑06‑30. The thesis: the price already embeds aggressive cash‑flow expectations, leaving little margin for error.
What the business actually is
Doximity runs a digital platform exclusively for U.S. medical professionals. The platform delivers a personalized newsfeed of clinical articles, video summaries of trials, peer updates, and sponsored content from pharma and health systems. Its workflow stack includes Ask, a HIPAA‑compliant AI assistant that surfaces evidence‑based answers inside clinical workflows, and Scribe, a documentation automation tool. Revenue is generated primarily from advertising and sponsorships sold to drugmakers and health systems that want access to the platform’s professional audience.
Why it can keep compounding
Profit margins sit at 25.5% and ROE at 18.2%, a pairing that signals a high‑return, capital‑light machine. The Quality pillar of 88 reflects that profitability and the network effect of a single‑source professional community—once a physician joins, the cost to retain them is low and the data moat widens. Competitors would need both a massive physician user base and HIPAA‑grade compliance to replicate Ask, a barrier that slows imitation. Our model flags “Durable high returns,” matching the $306 million in free cash flow and the debt‑to‑equity of 0.01. The platform’s ability to monetize the same audience through ads, sponsorships, and AI‑enabled services underpins the 11.2% revenue growth reported year‑over‑year.
The valuation question
A P/E of 30.7 and a PEG of 0.59 suggest the market rewards growth, yet the reverse‑DCF reveals the real assumption. To justify today’s price, the market embeds 7% free‑cash‑flow growth for ten years, a pace that exceeds the 11.2% FY revenue growth and would require margins to stay near 25.5% without further expansion. The analyst consensus target of $29.39 offers modest upside, while the 52‑week high of $76.51 shows the stock once commanded a far richer multiple. The Value pillar at 79 signals that, relative to peers, DOCS is not cheap on a cash‑flow basis; the cheapness is only on earnings, not on the cash‑flow growth story the market is pricing in. The market is optimistic—it expects the AI assistant and ad stack to accelerate cash generation beyond the historical trend.
The bear case
Critics argue the P/E of 30.7 is too steep for a company growing revenue just 11.2% YoY. If Ask fails to scale, cash‑flow growth could revert to historical rates, making the 7% implied growth unrealistic. A concrete red flag would be a pullback in pharma ad spending, which would compress the 25.5% profit margin and erode free cash flow. The Yahoo Finance take that the stock looks cheap on cash flow yet fair on earnings underscores that the market may already be overpaying for earnings while ignoring cash‑flow risk.
What would change our mind
First, an acceleration of revenue growth to a level that comfortably supports 7% cash‑flow expansion would validate the premium. Second, margin expansion beyond 25.5%, perhaps through higher‑margin AI subscriptions, would improve free‑cash‑flow generation and lift the Value pillar. Third, a sustained rise in debt‑to‑equity above 0.01 could signal capital‑intensive expansion that threatens the high‑return profile, confirming the bear’s view. Until one of those catalysts appears, the current price remains a bet on growth that outpaces the company’s proven track record.